Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

Abstract Objective The concept of “platinum sensitivity” has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer. Patients and methods In this multicenter retrospective cohort study, the cli...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2013-12, Vol.131 (3), p.567-573
Main Authors: Nagao, Shoji, Nishio, Shin, Michimae, Hirofumi, Tanabe, Hiroshi, Okada, Satoshi, Otsuki, Takeo, Tanioka, Maki, Fujiwara, Keiichi, Suzuki, Mitsuaki, Kigawa, Junzo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Cisplatin - administration & dosage
Cohort Studies
Disease-Free Survival
Doxorubicin - administration & dosage
Endometrial Neoplasms - drug therapy
Endometrial Neoplasms - pathology
Female
Hematology, Oncology and Palliative Medicine
Humans
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Obstetrics and Gynecology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - pharmacology
Paclitaxel - administration & dosage
Platinum sensitivity
Platinum-based chemotherapy
Recurrent endometrial cancer
Retrospective Studies
Second-line chemotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective The concept of “platinum sensitivity” has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer. Patients and methods In this multicenter retrospective cohort study, the clinical data of patients with recurrent endometrial cancer, who had a history of receiving first-line platinum-based chemotherapy and who received second-line platinum-based chemotherapy at the time of recurrence between January 2005 and December 2009 were reviewed. Results A total of 262 patients from 30 centers with initial FIGO stage classifications of I (29), II (23), III (122), and IV (88) were enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and 22 “other” tumors were documented. The response rates for patients with platinum-free intervals of < 6 months, 6–11 months, 12–23 months, and ≥ 24 months were 25%, 38%, 61%, and 65%, respectively. The median progression-free survival after second-line platinum-based chemotherapy for patients with platinum-free intervals of < 12 months and ≥ 12 months was 4.4 (95% confidence interval (CI) = 3.7–5.8) months and 10.3 (95% CI = 8.2–12.6) months, respectively (log-rank P < 0.0001), and the median overall survival was 13.8 (95% CI = 10.6–18.1) months and 40.9 (95% CI = 25.3–54.2) months, respectively (log-rank P < 0.0001). Conclusion Platinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer. The concept of “platinum sensitivity” could be applicable to recurrent endometrial cancer.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2013.09.021